- Home
- GDEN vs TRVI Comparison
GDEN vs TRVI Comparison
Compare GDEN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- TRVI
- Stock Information
- Founded
- GDEN 1998
- TRVI 2011
- Country
- GDEN United States
- TRVI United States
- Employees
- GDEN N/A
- TRVI N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- TRVI Health Care
- Exchange
- GDEN Nasdaq
- TRVI Nasdaq
- Market Cap
- GDEN 727.9M
- TRVI 725.7M
- IPO Year
- GDEN 1999
- TRVI 2019
- Fundamental
- Price
- GDEN $30.70
- TRVI $5.98
- Analyst Decision
- GDEN Buy
- TRVI Strong Buy
- Analyst Count
- GDEN 6
- TRVI 9
- Target Price
- GDEN $37.00
- TRVI $19.94
- AVG Volume (30 Days)
- GDEN 212.6K
- TRVI 2.2M
- Earning Date
- GDEN 08-07-2025
- TRVI 08-07-2025
- Dividend Yield
- GDEN 3.30%
- TRVI N/A
- EPS Growth
- GDEN N/A
- TRVI N/A
- EPS
- GDEN 0.39
- TRVI N/A
- Revenue
- GDEN $653,614,000.00
- TRVI N/A
- Revenue This Year
- GDEN $1.48
- TRVI N/A
- Revenue Next Year
- GDEN $2.88
- TRVI N/A
- P/E Ratio
- GDEN $78.05
- TRVI N/A
- Revenue Growth
- GDEN N/A
- TRVI N/A
- 52 Week Low
- GDEN $22.66
- TRVI $2.36
- 52 Week High
- GDEN $35.49
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- GDEN 68.28
- TRVI 48.75
- Support Level
- GDEN $29.04
- TRVI $5.41
- Resistance Level
- GDEN $30.93
- TRVI $5.96
- Average True Range (ATR)
- GDEN 0.82
- TRVI 0.30
- MACD
- GDEN 0.20
- TRVI -0.03
- Stochastic Oscillator
- GDEN 94.42
- TRVI 53.02
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.